Dasatinib tablets (20mg, 50mg, 70mg, 100 mg): Uses, Side Effects

Dasatinib tablets

  • Medicine Name – Spnib
  • API – Dasatinib
  • Pack Size – 30 & 60 Tablets
  • Strength – 20 mg, 50 m mg, 70 mg and 100 mg
  • Manufactured by – Zydus Cadila
Get an Enquiry
Category: Tag:

Description

Dasatinib is a kinase inhibitor indicated for the treatment of  

  • newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The trial is ongoing and further data will be required to determine long-term outcome. 

  • adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. 

  • adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

Dosage and Side Effects

  • Chronic phase CML: 100 mg once daily.

  • Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL: 140 mg once daily. 

Administer orally, with or without a meal. Tablets should not be crushed or cut.

Warning and Precautions

  • Myelosuppression: Severe thrombocytopenia, neutropenia, and anemia may occur and require dose interruption or reduction. Monitor complete blood counts regularly.  

  • Bleeding Related Events (mostly associated with severe thrombocytopenia): CNS and gastrointestinal hemorrhages, including fatalities, have occurred. Severe hemorrhage may require treatment interruptions and transfusions. Use Dasatinib with caution in patients requiring medications that inhibit platelet function or anticoagulants. 

  •  Fluid Retention: Dasatinib is associated with fluid retention, sometimes severe, including ascites, edema, and pleural and pericardial effusions. Manage with appropriate supportive care measures. 

  •  QT Prolongation: Use Dasatinib with caution in patients who have or may develop prolongation of the QT interval. 

  •  Congestive Heart Failure, Left Ventricular Dysfunction and Myocardial Infarction: Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.

  •  Fetal harm may occur when administered to a pregnant woman. Women should be advised of the potential hazard to the fetus and to avoid becoming pregnant.

FAQ's

Is Dasatinib approved by the FDA?

The FDA approved Dasatinib in 2006.

What is the indication for use of Dasatinib?

The medicine Dasatinib is recommended for the treatment of:  

  • Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
  • Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML.

Is Dasatinib a chemo drug?

Dasatinib is an oral anticancer targeted therapy classified as a BCR-ABL tyrosine kinase inhibitor (TKI) and is used to treat certain types of blood or bone marrow cancer.

Related products